ArticleFrontiers in oncology2026
Prostatectomy versus definitive radiation for localized prostate cancer: revisiting the debate at a tertiary cancer center.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Surgery and radiotherapy are the main treatments for localized prostate cancer. Although many retrospective studies have compared their efficacy, evidence from the Middle East and North Africa (MENA) region is limited. This study reports real-world outcomes of patients treated with radical prostatectomy versus definitive radiotherapy at a tertiary cancer center in Jordan. Methods: We conducted a retrospective cohort study of patients treated between June 2006 and June 2019. Patient demographics, disease characteristics, and treatment details were extracted from electronic medical records. Primary endpoints were cancer-specific survival (CSS) and overall survival (OS); secondary endpoints included metastasis-free survival (MFS) and biochemical relapse-free survival (BRFS). Survival outcomes and group differences were evaluated with the log-rank test. Results: Among 317 patients, median age was 68 years and median PSA 12.98 ng/mL. High-risk disease predominated (62.5%), followed by intermediate (32.8%) and low-risk (4.7%). Eighty-nine patients underwent radical prostatectomy and 228 received radiotherapy with androgen deprivation therapy (ADT). Five-year CSS and OS were excellent and similar between surgery and radiotherapy (CSS: 98.7% vs. 96.7%; OS: 90% vs. 89.6%). MFS was comparable (94.9% vs. 94.2%), while BRFS was lower in the surgical group (59.8% vs. 90.5%, p < 0.001). Recurrence occurred in 44.9% of surgical versus 14% of radiotherapy patients, and prostate cancer-specific deaths were 4.4% and 4.3%, respectively. Conclusion: This study shows that surgery and radiotherapy achieve excellent long-term survival for localized prostate cancer. Radiotherapy with ADT provides superior biochemical control, emphasizing the importance of individualized, multidisciplinary treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.